April 2025 in “International Journal of General Medicine” The G allele of IFITM3 rs12252 is linked to more severe COVID-19.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
1 citations
,
April 2018 in “Infectious diseases in clinical practice” Travel history and tick-borne diseases should be considered in unexplained fevers for timely diagnosis and treatment.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
16 citations
,
October 2013 in “Irish Veterinary Journal” Oral feline interferon-omega improved symptoms in diabetic cats with gingivostomatitis.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
2 citations
,
July 2025 in “RMD Open” IL-1 blockade is effective for treating SURF, and personalized treatment is needed.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
September 2017 in “Griffith Research Online (Griffith University, Queensland, Australia)” Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
April 2025 in “Suez Canal University Medical Journal” Valproic acid can rarely cause fluid buildup around the lungs and heart.
60 citations
,
September 2004 in “Pediatric Dermatology” A girl developed vitiligo and psoriasis after hepatitis B treatment, and stopping the treatment didn't help.
4 citations
,
October 2020 in “Research Square (Research Square)” Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
January 2003 in “Hepatology” 48 citations
,
August 2022 in “Chemical Biology & Drug Design” Computer-aided methods can speed up COVID-19 drug discovery and help find new uses for existing drugs.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
December 2025 in “International Journal of Surgery” GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
January 2026 in “Food Science and Human Wellness” Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.
Maidenhair fern might help with COVID-19 symptoms, but it needs more testing.
January 2014 in “대한피부과학회지” A hepatitis B patient lost hair in patches after starting and stopping a treatment with pegylated interferon alpha2a.
30 citations
,
February 2021 in “Journal of Medical Virology” TMPRSS2 affects COVID-19 severity and treatment options.
October 2024 in “Cermin Dunia Kedokteran” Effective monitoring and prevention strategies are needed to manage the spread of hand, foot, and mouth disease in children.
August 2025 in “Frontiers in Pharmacology” [6]-Gingerdiol 3-monoacetate shows promise for treating T. whipplei infections.
10 citations
,
October 2015 in “Journal of the International Association of Providers of AIDS Care” A woman with HIV had a severe skin condition that improved with antiretroviral therapy.
2 citations
,
August 2020 in “Journal of Nutritional Science and Vitaminology” Yellow Chinese chive extract helps protect mouse livers from damage caused by acetaminophen by activating an antioxidant pathway.
October 1977 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
8 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Hepatitis C treatment may trigger complete hair loss, especially in those with a history of patchy hair loss, but hair usually grows back within a year.
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.